Remikiren

drugbox
IUPAC_name=(2"R")-2-(tert-butylsulfonylmethyl)-"N"- [(2"S")-1-
{ [(2"R",3"S",4"R")-1-cyclohexyl-4-cyclopropyl-3,4-
dihydroxybutan-2-yl] amino}-3-(3"H"-imidazol-
4-yl)-1-oxopropan-2-yl] -3-phenylpropanamide

---

CAS_number=126222-34-2
ATC_prefix=C09
ATC_suffix=XA01
ATC_supplemental=
PubChem=5462340
DrugBank=APRD00163
C=33|H=50|N=4|O=6|S=1
molecular_weight=630.839 g/mol
bioavailability=
protein_bound=83%
metabolism=
elimination_half-life=
excretion=
pregnancy_AU=
pregnancy_US=
pregnancy_category=
legal_AU=
legal_UK=
legal_US=
legal_status=
routes_of_administration=

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996. [cite journal |author=Richter WF, Whitby BR, Chou RC |title=Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals |journal=Xenobiotica |volume=26 |issue=3 |pages=243–54 |year=1996 |pmid=8730917 |doi=]

References